| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CONCISE REVIEW |
University of Michigan Medical Center, Department of Internal Medicine, Division of Hematology/Oncology, Ann Arbor, Michigan, USA
Key Words. Interleukin 1 • Neoplasms • Review • Clinical trials • Toxicity • Antitumor effects • Hematopoietic effects
Dr. John W. Smith II, University of Michigan Medical Center, Department of Internal Medicine, Division of Hematology/Oncology, 3119 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0374, USA.
Clinical trials of interleukin 1
(IL-1) and IL-1ß have been completed that assess the toxicities of these cytokines as well as their hematopoietic and antitumor effects. Both forms of IL-1 recognize the same cell surface receptors and have similar toxicities and similar biological activities. Toxicities including fever, flu-like symptoms and dose-limiting hypotension can be severe yet manageable, and IL-1 can be given safely to human cancer patients. Most toxicities and biological effects appear to be dose-related. IL-1 alone has little antitumor activity against melanoma, renal cell carcinomas or other malignancies. The hematopoietic effects, including megakaryocytopoietic effects, are modest and are probably not worth the toxicity necessary to achieve them. However, IL-1 seems to endow certain progenitor cells with responsiveness to other hematopoietic cytokines including colony-stimulating factors and IL-3. One potential application of IL-1 is to help expand bone marrow ex vivo following stem cell harvest, which could allow further chemotherapy dose escalations in chemotherapy-sensitive tumors.
This article has been cited by other articles:
|
|
 |
|
  K.-H. Lee, S. S. Park, I. Kim, J. H. Kim, E. K. Ra, S.-S. Yoon, Y.-C. Hong, S. Park, and B. K. Kim P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation Haematologica, May 1, 2007; 92(5): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-E. Murphy, R. E. Morales, J. Scott, and T. S. Kupper IL-1{alpha}, Innate Immunity, and Skin Carcinogenesis: The Effect of Constitutive Expression of IL-1{alpha} in Epidermis on Chemical Carcinogenesis J. Immunol., June 1, 2003; 170(11): 5697 - 5703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Hefler, E. Ludwig, A. Lebrecht, R. Zeillinger, D. Tong-Cacsire, H. Koelbl, S. Leodolter, and C. B. Tempfer Polymorphisms of the Interleukin-1 Gene Cluster and Ovarian Cancer Reproductive Sciences, November 1, 2002; 9(6): 386 - 390. [Abstract] [PDF]
|
|
|
|
 |
|
 C. P. Bradney, G. D. Sempowski, H.-X. Liao, B. F. Haynes, and H. F. Staats Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization J. Virol., January 15, 2002; 76(2): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Christ, S. Matzku, C. Burger, and M. Zöller Interleukin 2-Antibody and Tumor Necrosis Factor-Antibody Fusion Proteins Induce Different Antitumor Immune Responses in Vivo Clin. Cancer Res., May 1, 2001; 7(5): 1385 - 1397. [Abstract] [Full Text]
|
|
|
|
|
|
O. Christ, S. Seiter, S. Matzku, C. Burger, and M. Zöller Efficacy of Local versus Systemic Application of Antibody-Cytokine Fusion Proteins in Tumor Therapy Clin. Cancer Res., April 1, 2001; 7(4): 985 - 998. [Abstract] [Full Text]
|
|
|
|
|
|
H. F. Staats and F. A. Ennis Jr. IL-1 Is an Effective Adjuvant for Mucosal and Systemic Immune Responses When Coadministered with Protein Immunogens J. Immunol., May 15, 1999; 162(10): 6141 - 6147. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
